BDNF and Parkinson disease: They utilized updated PRISMA guidelines [158] and used potential indicators of PD progression, including MDS UPDRS scores, BDNF and TNFα levels, neuroimaging of dopamine receptor binding and other brain structures, and neurophysiological test outcomes.